1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Europe Rare Neurological Disease Treatment Market to 2027 - Regional Analysis and Forecasts by Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Country

Europe Rare Neurological Disease Treatment Market to 2027 - Regional Analysis and Forecasts by Indication ; Drug Type ; Distribution Channel ; Mode of Administration and Country

  • April 2020
  • 154 pages
  • ID: 5894548
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

Europe, the rare neurological disease treatment market, is anticipated to reach US$ 3,763.41 Mn in 2027 from US$ 2,048.10 Mn in 2019. The market is projected to grow with a CAGR of 8.1% from 2020-2027.
The rare neurological disease treatment market is growing primarily due to the rising prevalence of rare neurological diseases, increasing awareness about rare diseases, and robust pipeline drugs in the Europe region that are boosting the market over the years.Restraining factors, such as higher cost of rare neurological disease treatments likely to damage the growth of the market in the coming years.

On the other hand, artificial intelligence for the treatment of rare neurological diseases is expected to have a positive impact on the growth of the Europe rare neurological disease treatment market in the coming years.
A large group of rare diseases that have inefficient diagnoses and treatments are the neurological disease.These diseases target the nervous system, which include the brain, spinal cord, and all the nerves that run throughout the human body.

There is no surety regarding the onset of the diseases; some can strike during childhood, whereas others can affect even highly aged people.
In the world of medicine, rare neurological diseases represent significant burden on health systems in terms of disease diagnosis, treatment, and management.Some of the majorly observed rare neurological diseases comprises narcolepsy, amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy (SMA), Duchenne muscular dystrophy, and others.

According to a data published by World Health Organisation (WHO), it is estimated that about 30 million Europeans in 27 EU-countries suffer from a rare disease.
Over the past few decades, various research and developmental works have been carried out pertaining to the diagnosis and management of rare neurological diseases.Advancements in healthcare systems and modernizing diagnostic systems are likely to enhance the screening operation for rare neurological diseases.

Additionally, increasing prevalence of rare neurological diseases is expected to drive the growth of the rare neurological disease treatment market during the forecast period.
In 2019, the Alzheimer’s disease accounted for the largest market share in the Europe rare neurological disease treatment market.Alzheimer’s disease is a progressive disease and a type of dementia, and the condition is characterized by eating and death of brain cells.

It is characterized by symptoms such as reduced thinking, memory loss, and lacking behavioural sense.These symptoms get worse over time and highly reduce the independently for daily routine.

The disease accounts for nearly 60% to 80% of all dementia cases.It is widely seen among the aging population.

In Germany, more than 1.5 million people are living with Alzheimer’s disease. For instance, In 2012, Alzheimer’s Europe reports that 1,572,104 individuals with dementia were in Germany. This constitutes 1.92 per cent of the total 81,990,837 population. The number of people with dementia is marginally higher than the EU average of 1.55 per cent.
In 2019, the biologics segment, held the most significant market share of the rare neurological disease treatment market by the drug type.This segment is also anticipated to be the fastest growing segment of the market in 2027, owing to the increasing neurological disorders, coupled with increasing robust hospital infrastructure and advancements in medicines, has enabled people for various treatments for the deadliest diseases.

Hence, the segment is anticipated to witness growth at a significant rate during the forecast period.
Some of the significant primary and secondary sources for cold plasma equipment included in the report are World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) and National Institute of Health (NIH)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on